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聚糖 - 超顺磁性氧化铁纳米粒 (SP5.2/tTF-o-Carboxymethylchitosan-superpara 
magnetic iron oxide nanoparticles, SP5.2/tTF-OCMCs-SPIO-NPs)。其中，SP5.2 多
肽组分能特异性靶向肿瘤血管内皮细胞高表达的 Flt1 受体；SPIO 磁核具有超顺
磁性，能够受外加磁场的引导定位到靶区，当磁场持续存在时又可以在高场强处






























静置法直接观察 SP5.2/tTF-OCMCs-SPIO-NPs 具有良好的稳定性（36 h 内无
沉降）。各项物化表征综合显示 SP5.2/tTF-OCMCs-SPIO-NPs 形态多呈类球形，
粒径小（约为 20-25nm），其表面成功偶联上了 SP5.2/tTF 和 OCMCs，提高了稳
定性，并保持良好的磁性能 (SPIO-NPs:66.1emu/g,OCMCs-SPIO-NPs:61.6emu/g, 
SP5.2/tTF-OCMCs-SPIO-NPs:58.4emu/g)。体外实验显示，SP5.2/tTF-OCMCs-SPIO 

























It is a promising anti-tumor strategy to selectively induce thrombosis in tumor 
blood vessels by using targeted vascular embolization drug. This strategy used 
guiding material (such as antibody, ligand or magnetic substance etc.) to carry the 
effector, then selectively localize effector to the tumor blood vessels to tumor vessels 
and induce thrombosis in tumor vasculature and cut off the nutrition or oxygen 
supplies of tumor, subsequently resulted in necrosis of the tumor and obtained 
anti-tumor effects. However, current research usually adopted the mode of monomer 
carrier combined with monomer effector whose therapeutic effect would not be 
satisfied, owing to the problem of insufficient binding, low loading drug carrier and 
slow effector targeting enrichment and deficiency concentration. To tackle these 
difficulties, present thesis constructed a multiple targeted magnetic nanoparticles drug: 
SP5.2/tTF-o-Carboxymethylchitosan-superparamagnetic iron oxide nanoparticles, 
short as SP5.2/tTF-OCMCs-SPIO-NPs. Thereinto, the SP5.2 pepetide moiety could be 
used to mediate specific binding to VEGFR-1 (Flt-1), which generally over-express 
on the neo-vascular endothelial cell surface. The SPIO magnetic core part possesses 
superparamagnetic property, which endow them with magnetic targeting by an applied 
magnet field guided. In addition, SPIO also be used as embolic materials directly, 
because it could be retained and fixed at as objective site when a magnet field 
persistently be supplied. Truncated tissue factor or tTF pessesses a powerful and 
specific coagulant once bound to the cell surface of the tumor vasculature by a 
targeting peptide. So SP5.2/tTF-OCMCs-SPIO-NPs likely could achieve the ability of 
double targeting to tumor blood vessels and multiple inducing embolization. 
OCMCs-SPIO-NPs were prepared by chemical coprecipitation, then surface 
conjugated the SP5.2/tTF proteins by glutaraldehyde to compose the SP5.2/tTF- 
OCMCs-SPIO-NPs magnetic nanoparticles composite finally. And directly observe 















And employed the scanning electron microscopy, X-ray diffraction, Fourier transform 
infrared spectroscopy and superconducting quantum interference device to 
characterized the SP5.2/tTF-OCMCs-SPIO-NPs composite, such as particle size, 
morphology, crystal structures, suface texture and magnetization etc. In vitro 
experiments, the peptide-directed targeting and magnetic field-guided targeted 
properties of composite evaluated by confocal microscopy and Prussian blue staining. 
Factor X coagulation assay to verify the blood coagulation abilities of the tTF moiety 
of composite. Cytotoxicity of composite was estimated by MTT assay, cellular uptake 
in different drug concentrations or different incubating times by ferrozine assay. 
Observe derectly the double-targeting activity of composite by fluorescence 
microscopy and Prussian blue staining. In vivo experiments, evaluated the tumor 
tissue location of composite by in vivo fluorescence imaging. Identified the 
double-targeting activity of composite in tissuse level by confocal microscopy and 
Prussian blue staining. Animal model of H22 tumor used to evaluate the inhibitory 
effect of tumor growth in mice with the different treatments. To evaluate the 
embolization effective against the different treatments by H&E staining histology 
analysis.  
As time goes on, SP5.2/tTF-OCMCs-SPIO-NPs solution retained stability in 36 h. 
And physicochemical characterization of SP5.2/tTF-OCMCs-SPIO-NPs showed that 
most of the particles are quasi-spherical or ellipsoidal with an average diameter of 
20-25 nm, SP5.2/tTF and OCMCs were successfully modified onto the SPIO-NPs 
surface, magnetic core were Fe3O4 with a hight saturation magnetization values 
(58.4emu/g) and pessess superparamagnetic properties. In vitro experiments showed 
that SP5.2/tTF-OCMCs-SPIO-NPs with double-targeting function and retain the 
Factor X activation, and has a significant decrease in the cell cytotoxicity, and the 
double-targeting property can enhance them accumulation at the cell surfaces. In vivo 
experiments, in vivo fluorescence imaging showed that composite could be located in 
and fixed at tumor tissue. Histology analysis showed that composite have 
double-targeting function in vivo, too. Tumor grouth was significantly inhibited with 















embolization in every treatment scheme except the saline and OCMCs-SPIO-NPs 
groups, and SP5.2/tTF-OCMCs-SPIO-NPs with magnetic field and intratumoral 
SP5.2/tTF-OCMCs-SPIO-NPs with magnetic field groups both have an extensiveness 
thrombotic vessels and necrotic tumor tissue. 
In summary, we have successfully prepared SP5.2/tTF-OCMCs-SPIO-NPs with a 
double-targeting property of peptide-directed targeting and magnetic field-guided 
targeted, which can more selectively and effectively to induce thrombosis in tumor 
blood vessels, inhibit the growth of tumor, and lead to the necrosis. Maybe this thesis 
provide a basis for developing a new drug in tumor blood vessels targeting therapy. 
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